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Introduction
Infections caused by Neisseria meningitidis are a serious threat to children and young adults. Vaccines based on capsular polysaccharides are available against serogroups A, C and W135 [1] . A polysaccharide-based vaccine is not available for serogroup B meningococci, due to the low immunogenicity of their polysaccharides and the risk of induction of autoantibodies that cross-react with glycosylated host antigens. Still, it remains important to develop new vaccines for serogroup B meningococci that make use of other antigenic epitopes in the outer membrane, as respectively 63% and 32% of the reported cases of meningococcal disease in Europe and the USA are attributable to serogroup B [2, 3] .
Class 1 porin protein (PorA) is a good vaccine candidate because is a major antigen and induces a strong bactericidal immune responses [4] . Serogroup B meningoccal vaccines are being developed by different groups, based on PorA formulated in outer membrane vesicles (OMV) [4, 5, 6] . However, despite purification, OMV still contain small amounts of toxic LPS. Furthermore, their composition is difficult to manipulate because it is governed by the strain from which the OMV are A rational approach for making better vaccines is to improve the delivery of (liposomal) antigens to dendritic cells (DC). Dendritic cells are the most efficient APC, being able to initiate and modulate immune responses both in vitro and in vivo [7] .
Several strategies can be conceived to target liposomes to DC. On the surface of DC, various receptors of the C-type lectin family are expressed, including the mannose receptor (MR) and DEC-205 [8] . Receptors of this family have in common the recognition of bacterial structures, and antigen capture by these receptors has been shown to result in an efficient antigen presentation [9, 10] . Another efficient uptake mechanism by DC and other APC is the endocytosis of apoptotic bodies. This is probably mediated by specific recognition of phosphatidylserine (PS) at the surface of apoptotic cells [11] .
The aim of this study was to design a well-defined PorA-based vaccine with improved immunogenicity compared to OMV by formulating PorA into liposomes targeted to DC. Three strategies were used to improve the uptake of PorA-liposomes by DC: liposomes with mannose ligands on the surface for targeting C-type lectin receptors; liposomes containing PS for targeting to the PS receptor; and positively charged liposomes to induce an efficient uptake mediated by non-specific electrostatic interactions with (negatively charged) DC membranes. As control, non-targeted negatively charged PorA-liposomes and OMV were used. In vitro, the uptake of targeted and non-targeted PorA-liposomes by bone marrow-derived murine DC was studied, as well as their ability to induce functional maturation of DC. In vivo, the localization of targeted liposomes (Man-liposomes) and non-targeted liposomes was compared in draining lymph nodes after subcutaneous immunization of mice.
Finally, the immune response of all liposomal PorA-formulations was studied in mice and compared with the immune response induced by (standard) OMV. Our data suggest that an increased antigen loading of DC through the use of targeted liposomes results in an improved immune response. Therefore, targeted liposomes are attractive presentation forms for future development of type B meningococcal vaccines.
Materials and methods

Materials
All phospholipids used were synthetic. Dimyristoyl phosphatidylcholine (PC) was purchased at Rhône-Poulenc Rorer (Köln, Germany). Dimyristoyl phosphatidylglycerol (PG) was a gift from Lipoïd GmbH (Ludwigshafen, Germany).
Cholesterol (Chol) was obtained from Sigma (Zwijndrecht, The Netherlands).
Dimyristoyl phosphatidylserine (PS), dimyristoyl phosphatidylethanolamine (PE) and dimyristoyl trimethylammonium propane (TAP) were purchased from Avanti Polar Lipids (Alabaster, AL). Mannosylated PE (Man-PE) was prepared by ethyldiisopropylamine-promoted coupling of PEA and mannopyranosylphenyl isothiocyanate (Sigma) in chloroform/methanol (7:1 v/v). The compound was purified by preparative TLC, and its structure was confirmed by nuclear magnetic resonance ( 1 H-NMR), liquid chromatography and mass spectrometry (LC-MS).
PorA was purified from outer membrane vesicles obtained from Neisseria meningitidis strain F91 (P1.7-2,4, PorB -, RmpM -, low expression of Opa/Opc) as previously described [12] . Prior to incorporation of PorA into liposomes, the protein was precipitated with 80% (v/v) ethanol at -20ºC and solubilized in 150 mM n-octyl β-d-glucopyranoside (Sigma) in Tris-buffered saline (TBS, containing 50 mM Tris-HCl, 150 mM NaCl pH 7.4).
Monoclonal antibodies against CD80 (clone 1G10), CD86 (clone GL1), FITClabeled mAb against CD11b (clone M1/70), phycoerythrin-labeled mAb against Gr-1 (clone RB6-8C5) and biotinylated mAb against CD11c (clone HL3) and CD45R/B220 (clone RA3-6B2) were obtained from BD PharMingen (San Diego, CA).
Streptavidin-phycoerythrin was purchased from Becton Dickinson (San Jose, CA).
Biotinylated mAb against F4/80 (clone Cl: A3-1) was obtained from Serotec (Oxford, UK). PE-labeled antiCD40 mAb (clone 3.23) was purchased from Immunotech (Marseille, France), and mouse anti-rat IgG (H+L) F(ab') 2 fragment was purchased from Jackson ImmunoResearch (West Grace, PA). M5/114 anti-MHC class II [13] was kindly provided by Dr. Georg Kraal (Vrije Universiteit, Amsterdam, The Netherlands).
Preparation and characterization of PorA-liposomes
Liposomes were made of PC, PG, Chol and Man-PE in a 8:2:2:0.6 mol ratio The correct folding of PorA into liposomes was analyzed by SDS-PAGE in 'native' gels as previously described [16] . Antigenicity of the P1.4 epitope of PorA P1.7-2,4 in liposomes was tested by an inhibition ELISA, with the monoclonal antibody MN20B9.34 as previously described [12] .
Mice
Balb/cOlaHsd mice were obtained from Harlan (Horst, The Netherlands) and maintained under conventional conditions at the Central Animal Laboratory, Utrecht University, the Netherlands or the Netherlands Vaccine Institute, Bilthoven, the Netherlands. All experiments were done with 8-12 weeks old animals and were approved by the Animal Ethics Committee.
Generation of DC and characterization following incubation with PorA-liposomes
Bone-marrow derived DC were obtained as described by Inaba et al. [17] .
Briefly, bone marrow was flushed from mouse femora, erythrocytes were lysed, and cells were grown at 1×10 6 /ml in filtered culture medium consisting of RPMI 1640 medium with 10% FBS, 50 IU/ml penicillin and 50 µg/ml streptomycin in the presence 
In vivo studies
Localization study: mice (3 animals per group) were immunized subcutaneously in the groin (0.25 ml, 1000 nmol phospholipid/mouse) with DiD-labeled PorA-liposomes. After 48 h, popliteal and inguinal lymph nodes located near the injection site were removed and pooled for each mouse. Lymph nodes were treated with 160 U/ml collagenase type 3 (Worthington Biochemicals, Lakewood, NJ) and 180 U/ml DNase I (Sigma) for 45 min at 37ºC and forced through a 70-µm filter.
The resultant cells were washed with FACS buffer and analyzed by flow cytometry as described above.
Immunization study: mice (8 animals per group) were immunized subcutaneously (0.25 ml/mouse) on day 0, 14 and 28 with 1.5 µg liposomal PorA or PorA-containing OMV. Sera were collected at day 42 and stored at -20ºC until analysis.
Serum analysis
The antibody titers (total IgG and individual isotypes) in mouse sera were determined in an ELISA as previously described [18] . Neisseira meningitidis strain H44/76 (B:15P1.7-2,4:L3,7,9) and the H44/76-derived mutant strain HI.5 (lacking PorA) were used. Isotypes were determined with goat anti-mouse (GAM) Ig isotypespecific conjugates, labeled with horseradish peroxidase (HRP) (Southern Technology Associates; dilution 1/5000, except for IgG1 1/2500), using tetramethyl benzidine (TMB) as substrate. The titer is defined as the dilution of the serum where 50% of the OD max (λ=450 nm) in the assay is reached. OD max is the absorbance obtained with 2-fold diluted serum.
The serum bactericidal activity was measured as previously described [19] against the N. meningitidis strains: H44/76 (B:15P1.7-2,4:L3,7,9) and HI5 (PorA -).
Sera from mice were heat inactivated for 30 min at 56ºC prior to use. Bacteria were incubated for 10 to 15 min at room temperature with the serum samples before the addition of complement. As complement source, 80% (v/v) rabbit serum was used.
As controls, the bactericidal anti-P1.4 (MN20B9.34) and anti-LPS (MN15A17F12) monoclonal antibodies were used. Also, test sera were incubated without complement as a negative control. The serum bactericidal titer was measured as the reciprocal serum dilution showing more than 90% killing of the number of bacteria used.
Statistical methods
Antibody and bactericidal titers were log 10 transformed in order to obtain a gaussian distribution. ANOVA was used for statistical evaluation of the data. The significance of the differences between the mean values of the antibody titers was determined by the least significant difference (LSD) test at a confidence level of 95%.
This test could not be used for bactericidal titers, as groups included both responders and non-responders. Individual values are given together with the mean of the indicated responders.
Results
Liposomal PorA formulations
All liposomes had particle sizes around 200 nm ( Table 1) . As expected, PG-, PS-and Man-liposomes were negatively charged, whereas TAP-liposomes were positively charged, as indicated by their zeta potential. The initial protein/lipid ratio (25 µg protein/µmol lipid) was preserved in the resulting liposomes. The presence of accessible mannose residues in the surface of Man-liposomes was confirmed by their aggregation in the presence of the carbohydrate binding lectin ConA (Fig. 1) .
A correct PorA conformation is necessary in order to induce an optimal B-cell response that will result in the production of protective, i.e. bactericidal, antibodies. In order to investigate the PorA conformation, SDS-PAGE under mild conditions was The ability of PorA-liposomes to interact with specific bactericidal mAb (i.e. (Fig. 3, inset) . (Fig. 3) . 
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Cells were also visualized by confocal microscopy (Fig. 4) . After incubation for 
Maturation and IL-12 production by liposome-pulsed DC
Bone marrow-derived DC were characterized with specific monoclonal antibodies (MHC Class II, CD80, CD86 and CD40) by flow cytometry (Fig. 5A ). Day 7 DC (t=0) showed moderate levels of MHC Class II and low levels of CD80, CD86 and CD40 expression. After 48 h incubation (day 9 DC), the levels of these markers were increased. LPS-pulsed DC showed a clear maturation, with increased expression of MHC Class II, CD80, CD86 and CD40.
All liposomal formulations induced increased levels of maturation markers on DC after 48 h incubation (Fig. 5B) . A substantial increase in MHC Class II (comparable to MHCII expression in LPS-pulsed DC), CD80, CD86 and CD40 expression was observed with all targeted PorA-liposomes (Man-, PS-and TAP-liposomes). Much less pronounced effects were observed for non-targeted (PG) liposomes, suggesting that enhanced uptake of PorA-liposomes through targeting leads to increased maturation.
The IL-12 concentration was measured in supernatants of DC pulsed with liposomes and LPS (Fig. 6) . After 48 h incubation, only targeted PorA-liposomes (Man-, PS-and TAP-liposomes) had induced IL-12 production to the same extent as LPS. Non-targeted liposomes failed to induce IL-12 production by cultured DC.
Differences were also found in the concentration of IL-12 in supernatants of the different types of targeted liposomes. For DC incubated with Man-liposomes, the IL-12 production was significantly higher than that of DC incubated with PS-or TAP-liposomes (p < 0.01). These findings suggest that, besides increased maturation, targeted PorA-liposomes induce functional maturation of DC. 
In vivo localization of PorA liposomes
The 
Immune responses generated by PorA liposomes
The immune response generated by PorA-liposomes and OMV was studied in vivo. All targeted liposomes (Man-, PS-and TAP-liposomes) were tested, together with non-targeted liposomes and OMV as control. This choice was based on in vitro data, where the antigenicity of PorA in PorA-liposomes was variable (lower for Manand TAP-liposomes than for PS-and PG-liposomes; Table 1 ). On the other hand, all targeted PorA-liposomes were able to improve the interaction with DC and induce their functional maturation (i.e. IL-12 production).
Sera (day 42) were analyzed not only for the presence of IgG and the IgG isotype distribution, but also for their functionality, i.e. complement-mediated bactericidal serum activity. Despite the variable antigenicity, all formulations induced similarly high IgG titers (Table 2 ). No differences were found in the isotype distribution of IgG in sera of mice immunized with the different liposomal PorA formulations and OMV. In contrast with what was expected from the in vitro data, the mean bactericidal titers of the responding mice were similar in all groups (Table 2) .
However, the percentage of responding mice increased in the groups immunized with targeted liposomes with respect to PG-liposomes and OMV (both non-targeted; Table 2 ).
Discussion
In this study, we designed well-defined liposomal PorA formulations, aiming to improve the immunogenicity of PorA. DC in the periphery capture and process antigens, express lymphocyte co-stimulatory molecules, migrate to lymphoid organs and secrete cytokines to initiate immune responses [7] . The question is then: does an enhancement of antigen loading of DC result in an improved immune response? In order to address this question, diverse strategies were chosen to increase the uptake of PorA-liposomes by DC: first, receptor-mediated targeting towards a) receptors with specificity for mannose (Man-liposomes) [9, 10] or b) the PS receptor (PS-liposomes) [11] ; second, increasing the uptake of PorA-liposomes by non-specific electrostatic interaction of positively charged liposomes (TAP-liposomes) with (negatively charged) DC.
The formulation of PorA in both Man-liposomes and TAP-liposomes resulted in a decreased ability of PorA to interact with specific mAb (Table 1) , despite the preservation of the trimeric protein conformation (Fig. 2) . This was probably due to steric hindrance caused by mannose molecules at the outside of the liposomes and the positive charge of TAP-liposomes, respectively, which hindered the interaction of PorA and its specific mAb.
Targeted PorA-liposomes showed an increased uptake by DC in vitro, as compared with non-targeted liposomes (Fig. 3) . Increased uptake has been ascribed to the multivalent character of liposomal antigens as compared with soluble antigens [20] . More efficient antigen presentation by DC was obtained by targeting liposomes towards Fc receptor or Class I/Class II molecules [20] . Also, mannosylated protein antigen and peptides showed enhanced potency to stimulate specific T cell clones as compared to non-mannosylated peptides [21] . More recently, the same has been proven with mannosylated liposomes [22] . However, these systems have only been tested in vitro and with model antigens. In our study, in vivo experiments were included as promising in vitro results are not always predictive for improved vaccine efficacy in vivo.
Our results confirmed that PorA-liposomes are efficiently internalized by cultured DC (Fig. 4) . The uptake of PorA-liposomes induced maturation of DC (Fig.   5 ). However, only targeted liposomes induced IL-12 production by DC (Fig. 6) . The improved uptake of Man-liposomes can be explained by the interaction of mannose moieties with receptors of the C-type lectin family (MR, DEC-205). For PS-liposomes, their increased internalization with respect to non-targeted liposomes can be explained by an uptake mechanism similar to that of apoptotic cells. Phagocytosis of apoptotic cells is related to the recognition of PS exposed externally due to the loss of asymmetry of plasma membrane phospholipids during apoptosis [23, 24] , by the PS receptor [25] . On the other hand, the uptake of positively charged TAP-liposomes is probably not receptor mediated, but caused by nonspecific electrostatic interactions with negatively charged DC. This mechanism is just as efficient mediating the uptake of PorA-liposomes as receptor-mediated endocytosis. The cytokines generated by DC are critically important for subsequent T-cell differentiation. IL-12 produced by DC is pivotal for the development of Th1 responses [26] . A Th1-type immune response can switch B-cells to IgG2a production [27] . This is preferable as IgG of the isotypes 2a and 2b are able to interact with complement and induce complement-mediated killing of bacteria [19] . Bactericidal antibody titers in human sera are considered one of the correlates of protection in type B meningococcal vaccination [28, 29] . It has been demonstrated that IL-12 is required for development of an effective cellular and/or humoral antimicrobial defense against bacteria [30] , parasites [31] and viruses [32] . Targeting Liposomes are well-defined systems composed of purified materials. In our experiments, liposomes contained LPS-depleted PorA and therefore offer an important safety advantage over LPS-containing OMV, which are the only PorA vaccines tested in the clinic so far [4, 5, 6] . LPS is a potent activator of DC [9] , as confirmed in this study ( Fig. 5 and 6 ), but is also a toxic compound, which should preferably be absent in vaccine formulations [33] .
In summary, targeted PorA-liposomes showed efficient loading and activation of cultured DC as compared to non-targeted PorA-liposomes. In line with these findings, improved uptake in draining lymph nodes as well as preferential uptake by APC was observed in vivo. Importantly, immunization with targeted PorA-liposomes resulted in a partial improvement of the immune response in comparison with non-targeted liposomes or OMV. However, the improvement in vivo is less pronounced that the strong effects seen in vitro. Our data encourage the development of meningococcal immunization strategies using antigens encapsulated in liposomes targeted towards APC.
